OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	731
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	719
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	251
A disseminated gonococcal infection with spinal locations	186
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	161
Reigniting the burnt-out health-care workforce	146
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	133
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	133
Research in Brief	131
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	112
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	110
Biological disease-modification in axial spondyloarthritis: insights from MRI	109
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	91
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	91
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	89
Women in rheumatology in Africa	87
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	84
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	81
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	80
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	76
Can contextual factors improve clarity of the results from clinical trials of low back pain?	71
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	71
Early-stage Dupuytren's disease treatment; a promising next step?	70
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	63
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	60

Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	57
Pausing drugs and spacing vaccines: an open question – Authors' reply	57
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	54
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	53
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	53
Composite endpoints for Sjögren's Syndrome	52
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	52
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	50
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	49
Research in Brief	48
Assessing glucocorticoid toxicity: are the measures sensitive enough?	44
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	44
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	44
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	43
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	42
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	42
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	42
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	42